Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) SVP Andrew Davis sold 5,360 shares of the business's stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.08, for a total value of $21,868.80. Following the completion of the sale, the senior vice president now directly owns 284,685 shares of the company's stock, valued at approximately $1,161,514.80. This trade represents a 1.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Ironwood Pharmaceuticals Price Performance
Shares of IRWD opened at $3.52 on Thursday. The company has a 50-day simple moving average of $4.25 and a two-hundred day simple moving average of $5.38. The firm has a market capitalization of $563.31 million, a PE ratio of -117.33 and a beta of 0.47. Ironwood Pharmaceuticals, Inc. has a one year low of $3.51 and a one year high of $15.70.
Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.07). The firm had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The company's revenue for the quarter was down 19.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.12 earnings per share. Analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Trump won. Buy this coin now.
From Weiss Ratings | Ad
Juan Villaverde called the top and bottom of every crypto bull market since 2012.
He believes Bitcoin will go to $150,000 — or more.
But there’s one coin he thinks could go even higher.
This could be his favorite coin.
Several brokerages have weighed in on IRWD. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a "hold" rating in a research report on Monday, September 9th. Craig Hallum cut their price target on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, August 9th. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Capital One Financial cut Ironwood Pharmaceuticals from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Finally, Wells Fargo & Company dropped their price objective on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an "overweight" rating for the company in a report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $10.40.
Read Our Latest Report on Ironwood Pharmaceuticals
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter worth approximately $91,000. US Bancorp DE raised its position in shares of Ironwood Pharmaceuticals by 14.9% in the 1st quarter. US Bancorp DE now owns 45,770 shares of the biotechnology company's stock worth $399,000 after purchasing an additional 5,930 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Ironwood Pharmaceuticals by 8.1% in the 1st quarter. ProShare Advisors LLC now owns 38,883 shares of the biotechnology company's stock worth $339,000 after purchasing an additional 2,917 shares during the last quarter. State Board of Administration of Florida Retirement System grew its position in Ironwood Pharmaceuticals by 339.4% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 195,057 shares of the biotechnology company's stock valued at $1,699,000 after purchasing an additional 150,663 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Ironwood Pharmaceuticals by 21.8% during the 1st quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company's stock valued at $170,031,000 after purchasing an additional 3,487,821 shares in the last quarter.
Ironwood Pharmaceuticals Company Profile
(
Get Free Report)
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
